Cervix disorder

This phase 2 trial tested a new treatment sequence for stage IB2 to IVA cervical cancer. Patients received a combination of gemcitabine and cisplatin chemotherapy along with radiation, followed by more gemcitabine. The goal was to see if this approach could improve progression-fr…

This early-phase trial tests whether using MRI scans to guide the placement of internal radiation (brachytherapy) can improve treatment for women with advanced cervical or vaginal cancers linked to HPV. The study involves 26 participants and compares MRI-guided placement to stand…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This early study tests a new CRISPR gene therapy (BD114) in 12 women with high-grade cervical lesions caused by HPV-16. The therapy is injected directly into the lesion to disable the virus's cancer-causing genes. The main goals are to check safety and see if the lesions clear up…

This trial investigates whether specially engineered immune cells (CAR-T cells) can safely treat advanced or recurrent cervical cancer. The cells are designed to recognize and attack cancer cells that carry certain markers like GD2 or Mesothelin. The study involves 20 adults with…

This study tests a new treatment for people with advanced or recurrent cervical cancer linked to high-risk HPV. The treatment uses specially engineered immune cells (CC-EIEs) designed to target and attack the cancer. Participants receive several infusions of these cells, and rese…

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

This trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…

This phase 2 study tested a personalized treatment called LN-145 for women with recurrent or advanced cervical cancer. The therapy uses a patient's own tumor-fighting immune cells, grown in a lab and infused back. The trial aimed to see if it could shrink tumors, but it was termi…

This phase 2 trial compares a new combination of camrelizumab (an immunotherapy) plus apatinib (a targeted therapy) against the standard chemotherapy plus bevacizumab as a first treatment for women with stage IVB, recurrent, or persistent cervical cancer. The study aims to see if…

This trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…

This trial tested a drug called tisotumab vedotin, alone or with other medicines, in people with cervical cancer that had come back or spread. The study included 214 participants and aimed to find the best dose and see if the tumors shrank. The trial was stopped early, but the re…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This study tested adding the immune-boosting drug pembrolizumab to standard chemoradiation for people with advanced cervical cancer. The goal was to see if the combination is safe and to find the best dose. Only one person was enrolled before the study was stopped early, so resul…

This early study tested a new treatment called GT201 for people with advanced gynecological tumors, like advanced cervical cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight the cancer. The study was terminated early after enrolling …

This phase 2 trial tested whether combining metformin (a diabetes drug) with doxycycline (an antibiotic) could help treat localized breast and uterine cancers. The study enrolled 29 people who were scheduled for surgery. Researchers looked at changes in certain proteins in the tu…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This phase 2 trial tested two immunotherapy drugs, AGEN2034 and AGEN1884, in 211 women with recurrent cervical cancer that had progressed after chemotherapy. One group received AGEN2034 alone, the other received both drugs. The goal was to see if the tumors shrank. The study was …

This study looked at whether adding a specific chemotherapy combination (carboplatin and paclitaxel) after standard chemoradiation could help people with advanced cervical cancer that has spread to lymph nodes near the kidneys. The trial planned to enroll 21 participants but was …

This early-phase trial tested a combination of two drugs—toripalimab (an immunotherapy) and chidamide (a targeted therapy)—in women with advanced cervical cancer that had spread or returned. Only 5 participants were enrolled before the study was terminated. The goal was to see if…

This study tested a vaginal insert called ABI-2280 in women with cervical precancerous lesions (CIN). The goal was to see if it was safe and could help clear the abnormal cells. The trial was stopped early, so we don't have full results. It involved 44 women aged 25-55 who used t…

This early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…

This study tested a drug called sacituzumab govitecan in people with ovarian, endometrial, or cervical cancer that returned after at least two rounds of standard treatment. The goal was to see if the drug could shrink or eliminate tumors. The study was terminated early with only …

This early-phase trial tested a new treatment called TC-E202 for people with advanced cervical cancer that had stopped responding to standard treatments. TC-E202 uses a patient's own immune cells, which are genetically modified in a lab to better recognize and attack cancer cells…

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This study looked at whether a less invasive surgery (conservative surgery) could safely treat women with early-stage, low-risk cervical cancer. The goal was to see if this approach causes fewer side effects and helps recovery. The study included 137 women with stage IA2 or IB1 c…

This early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.

This study tested whether offering a home urine test for human papillomavirus (HPV) could encourage more women to get screened for cervical cancer. The trial targeted women aged 30–65 in Brittany, France, who had not responded to an initial invitation for a Pap smear. Participant…

This study compared two devices used to collect tissue from the cervix during screening for cervical cancer: the standard Kevorkian curette and a softer cytobrush. The goal was to see if the cytobrush causes less pain while still getting enough cells for diagnosis. Only 3 women w…

This very early trial tested a single dose of HB-201 in 10 people with HPV 16+ throat or cervical cancer. The goal was to see how the drug affects the immune system, not to treat the cancer. The study was terminated early, so results are limited.

This study looked at whether providing support for unmet basic needs—like food, housing, or transportation—helps low-income women attend their colposcopy appointment after an abnormal cervical cancer screening. The trial planned to enroll 72 participants but was stopped early wit…

This study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope t…

This study looked at whether MRI and PET scans taken two weeks into radiotherapy can predict if cervical cancer will be controlled. Researchers measured tumor size and activity in 9 patients with stage I to IIIB cervical cancer. The goal was to find early signs of treatment failu…

This study aimed to find a better way to detect pelvic floor problems caused by radiation treatment for gynecologic cancer. Researchers tested a 5-minute single-digit pelvic exam on 22 patients undergoing chemoradiotherapy for cervical cancer. The goal was to see if this exam cou…

This study looked at whether tumor DNA floating in the blood of cervical cancer patients can help detect early spread of the disease. Researchers took blood samples from 26 patients before, during, and after treatment. The goal was to see if this DNA test could find minimal metas…